Sun, Jan 21, 2018 - Page 9 News List

Google venture arm backs UK universal flu vaccine company

Vials of flu vaccines for the year are shown in the picture photographed on Jan. 10, 2013 in Philadelphia, the USA. A UK company is developing a universal flu vaccine.

Photo: AP

vaccine that would be the first in the world to fight all types of flu has raised 20 million pounds (US$27 million) from investors including GV, the venture capital arm of Google parent Alphabet Inc.

Vaccitech, a spin-out founded by scientists at Oxford University’s Jenner Institute, said on Monday the cash would help fund its vaccine through a two-year clinical trial involving more than 2,000 patients and expand other projects.

The group is also running clinical studies on an experimental shot to prevent Middle East Respiratory Syndrome (MERS) and a therapeutic prostate cancer vaccine for use with an immunotherapy drug. Recent advances have made such vaccine-drug combinations a hot area of cancer research.

A so-called universal flu vaccine that elicits immunity against parts of the virus that do not change from year to year is a holy grail of medicine — but so far it has proved elusive.

Current flu vaccines have to be changed each year to match strains of virus circulating at the time. The hope is the new one-size-fits-all vaccine will provide better and longer-lasting protection.

Vaccitech’s new vaccine works by using proteins found in the core of the virus rather than those on its surface. Surface proteins stick out like pins from the virus and change all the time, while those in the core are stable.

It also stimulates T-cells rather than antibodies, an approach that has yet to convince existing flu vaccine manufacturers like Sanofi, GlaxoSmithKline and CSL’s Seqirus.

Still, Vaccitech Chief Executive Tom Evans is confident the big players will come around if the current mid-stage clinical trial is a success and he will not have a problem in finding a partner to take the product into final-stage Phase III tests.


vaccine n.


(yi4 miao2)

clinical adj.


(lin2 chuang2 shang4 de5)

elusive adj.


(nan2 yi2 zhang3 wo4)

game-changer phr.


(dian1 fu4 xian4 zhuang4 de5 ren2 shi4 wu4)

take a long view phr.


(ba3 mu4 guang1 fang4 chang2 yuan3)

“If we get positive data that shows we can affect rates of hospitalisation and illness with influenza then there is no question in my mind that a partner would take this on,” he told Reuters. “This could be a game-changer in a very competitive market.”

The Vaccitech trial marks the first time that a universal flu vaccine has progressed beyond Phase I clinical testing.

If all goes well, Vaccitech’s shot could potentially be ready for launch in 2023, although Evans said 2024 or 2025 might be more realistic. That means financial backers need to take a long view, especially as its other programmes using T-cells to make vaccines against cancer, MERS, hepatitis B and human papillomavirus are also at an early stage.

“We wanted people who were willing to stick with us for a while and had bigger pockets for doing secondary rounds,” Evans said.


英國一家私人公司正在研發一種世界首見,可對抗所有類型流感的萬能疫苗。該公司目前已籌措到兩千萬英鎊(兩千七百萬美元)的資金,投資者包括Google創投(GV),也就是Google母公司Alphabet Inc的投資部門。









This story has been viewed 4010 times.

Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

TOP top